Saturday 17 October 2026
Export VECT’s income statement to Excel — free account
VectivBio Holding AG
VECT Healthcare Biotechnology
VectivBio Holding AG’s revenue for fiscal 2022 (year ended December 2022) was $27.3 million.
Follow VECT
VectivBio Holding AG (VECT) P/E ratio
VectivBio Holding AG has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (July 2023) to 0.0× (July 2023) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CTMX CytomX Therapeutics, Inc. compare | n/m |
| STTK Shattuck Labs, Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| DBVT DBV Technologies S.A. compare | n/m |
| VECT VectivBio Holding AG | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 18.2× |
| VALN Valneva SE Sponsored ADR compare | 59.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)